In the race to develop COVID-19 vaccines, Novavax (NASDAQ: NVAX) seems to have gotten the most important part right. The latest clinical trial data for the NVX-CoV2373 vaccine showed 90% overall efficacy against early variants after demonstrating 96% efficacy against the original strain. Novavax is expected to file for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in September, after which more data should be forthcoming.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting